Rafferty Asset Management’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-12,352
| Closed | -$1.32M | – | 1078 |
|
|
2023
Q2 | $1.32M | Buy |
12,352
+3,032
| +33% | +$323K | 0.01% | 748 |
|
|
2023
Q1 | $2.78M | Buy |
+9,320
| New | +$2.78M | 0.02% | 522 |
|
|
2022
Q2 | – | Sell |
-5,808
| Closed | -$1.94M | – | 1144 |
|
|
2022
Q1 | $1.94M | Sell |
5,808
-357
| -6% | -$119K | 0.01% | 607 |
|
|
2021
Q4 | $2.01M | Buy |
6,165
+2,427
| +65% | +$789K | 0.01% | 659 |
|
|
2021
Q3 | $1.82M | Sell |
3,738
-568
| -13% | -$276K | 0.01% | 665 |
|
|
2021
Q2 | $2M | Sell |
4,306
-127
| -3% | -$59K | 0.01% | 684 |
|
|
2021
Q1 | $3.06M | Buy |
4,433
+3,081
| +228% | +$2.13M | 0.02% | 480 |
|
|
2020
Q4 | $999K | Sell |
1,352
-1,408
| -51% | -$1.04M | 0.01% | 492 |
|
|
2020
Q3 | $1.91M | Buy |
2,760
+1,887
| +216% | +$1.31M | 0.02% | 428 |
|
|
2020
Q2 | $740K | Buy |
+873
| New | +$740K | 0.01% | 618 |
|